WW announced on Thursday that it will be laying off employees and cutting costs to the tune of $100 million per year.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
A patent for generative neural network-based ultrasounds from medical device firm Philips could provide more data to develop AI innovations throughout…
Pfizer, Moderna, and GlaxoSmithKline are developing vaccines for RSV to fill the gap on their balance sheets.
Walgreens’ new leader is planning a rebound for the chain, starting with shuttering a substantial, if unspecified, number of US locations.
The Department of Health announced this week that Medicare is cutting prices for dozens of prescription drugs that have outpaced inflation.
Novo Nordisk scored approval to sell its Wegovy weight loss drug in China. That’s a big win, but competitors will soon flood in.
As the frequency of cyberattacks on healthcare systems and hospitals increases, so too do the costs for preventing them.
A recent trial showed its new 2-for-1 injection was more effective on both illnesses than existing individual shots.
Last year saw the highest private in-patient admissions since records began, totaling roughly 900,000, a 7% increase from 2022.
A loophole lets the company create a back-door offering of a generic drug before the patents of Novo Nordisk and Eli Lilly expire.
Moderna says it was willing to licence the tech but now wants to be repaid by rivals for vaccine revenue generated since then.
The figure was enough to push the insurance giant to a loss in Q1, despite its revenue beating expectations.
The company announced positive results in an early-stage trial of the individualized cancer vaccine it developed with Merck.
The filings signal the growing use cases for AI in healthcare settings, but also the risks that may accompany using AI in clinical care.
A GLP-1 medication from French drugmaker Sanofi — similar to Ozempic — was found to slow Parkinson’s in a small mid-stage trial.
Demand for senior living facilities is inching back toward pre-pandemic levels. But how that demand will be met is still an open question.